Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery (vol 7, pg 561, 2017)

被引：0
|
作者：
Guerrero-Zotano, Angel L.
Arteaga, Carlos L.
机构：
来源：
CANCER DISCOVERY | 2019年 / 9卷 / 02期
关键词：
D O I：
10.1158/2159-8290.CD-18-1516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
    Guerrero-Zotano, Angel L.
    Arteaga, Carlos L.
    [J]. CANCER DISCOVERY, 2017, 7 (06) : 561 - 574
  • [2] Drug discovery for a newgeneration of covalent drugs (vol 7, pg 561, 2012)
    Kalgutkar, A. S.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2012, 7 (09) : 861 - 861
  • [3] Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development
    Beaver J.A.
    Amiri-Kordestani L.
    Philip R.
    Cortazar P.
    [J]. Current Breast Cancer Reports, 2015, 7 (3) : 151 - 160
  • [4] Axillary Downstaging in ER+/HER2- Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach
    Kantor, Olga
    Coopey, Suzanne B.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (03) : 1265 - 1267
  • [5] Axillary Downstaging in ER+/HER2− Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach
    Olga Kantor
    Suzanne B. Coopey
    [J]. Annals of Surgical Oncology, 2021, 28 : 1265 - 1267
  • [6] Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (vol 28, pg 626, 2022)
    Marron, Thomas U.
    Galsky, Matthew D.
    Taouli, Bachir
    Fiel, Maria Isabel
    Ward, Stephen
    Kim, Edward
    Yankelevitz, David
    Doroshow, Deborah
    Guttman-Yassky, Emma
    Ungar, Benjamin
    Mehandru, Saurabh
    Golas, Benjamin J.
    Labow, Daniel
    Sfakianos, John
    Nair, Sujit S.
    Chakravarty, Dimple
    Buckstein, Michael
    Song, Xiaoyu
    Kenigsberg, Effi
    Gnjatic, Sacha
    Brown, Brian D.
    Sparano, Joseph
    Tewari, Ashutosh
    Schwartz, Myron
    Bhardwaj, Nina
    Merad, Miriam
    [J]. NATURE MEDICINE, 2022, 28 (08) : 1723 - 1723
  • [7] The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
    Spring, Laura
    [J]. ONCOLOGIST, 2018, 23 : S4 - S4
  • [8] Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer (vol 20, pg 3222, 2014)
    不详
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2825 - 2825
  • [9] Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2-primary breast cancer: CheckMate 7FL
    Loi, Sherene
    McArthur, Heather
    Harbeck, Nadia
    Pusztai, Lajos
    Delaloge, Suzette
    Letrent, Kristen
    Chen, Tian
    Li, Bin
    Tatsuoka, Kay
    Zardavas, Dimitrios
    Curigliano, Giuseppe
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [10] PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2-breast cancer
    Lopez Velazco, J. I.
    Manzano, S.
    Elorriaga, K.
    Lahuerta Martinez, A.
    Alvarez, L. A.
    Etxabe Azkue, I.
    Huarte Martinez, M.
    Buch, E.
    Gimenez Climent, J.
    Quiroga Garcia, V.
    Aragon, S.
    Pare, L.
    Prat, A.
    Alvarez Lopez, I.
    Munoz Caffarel, M.
    Urruticoechea, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S168 - S169
12345